补肾健脑法治疗帕金森病的疗效观察

The therapeutic effect of kidney tonifying and brain strengthening therapy on Parkinson’s disease

目的探究艾司西酞普兰联合乌灵胶囊治疗帕金森病的疗效及对血清去甲肾上腺素(NE)、5-羟色胺(5-HT)、白细胞介素-1β(IL-1β)、脑源性神经营养因子(BDNF)水平的影响。方法选取2018年6月至2020年8月在济南市人民医院接受治疗的90例帕金森病患者,在组间基线特征匹配的基础上,按照随机数字表法分为联合组(45例)和对照组(45例)。其中联合组给予乌灵胶囊联合艾司西酞普兰治疗,对照组给予艾司西酞普兰治疗。对比两组患者日常生活活动能力评定量表(ADL)、帕金森统一评分量表(UPDRS)评分,血清5-HT、BDNF、NE、IL-1β水平及临床疗效。结果治疗后,两组患者血清IL-1β、UPDRS评分均降低,且联合组更低(P<0.05);ADL评分、5-HT、BDNF、NE均升高,且联合组更高(P<0.05);联合组患者的总有效率为91.11%,高于对照组的71.11%,差异有统计学意义(P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05)。结论乌灵胶囊联合艾司西酞普兰治疗帕金森病,可有效提高血清5-HT、BDNF、NE水平,降低血清IL-1β水平,减轻患者炎症反应,提升日常生活能力,安全有效。

Objective To explore the efficacy of escitalopram with Wuling Capsule combined in the treatment of Parkinson’s disease and its influences on levels of serum norepinephrine(NE),5-hydroxytryptamine(5-HT),interleukin-1β(IL-1β),and brain-derived neurotrophic factor(BDNF).Method During June 2018 to August 2020,90 patients with Parkinson’s disease who were treated in our hospital were selected and randomly separated into a combination group(45 cases)and a control group(45 cases).The combination group was given Wuling Capsule combined with escitalopram,and the control group was treated with escitalopram.The scores of Activity of Daily Living(ADL),and Unified Parkinson’s Disease Rating Scale(UPDRS),the levels of serum 5-HT,BDNF,NE,and IL-1β,and clinical efficacy were compared between the two groups.Result After treatment,serum IL-1βlevels in the two groups were significantly lower than those before treatment(P<0.05),and those in the combined group were lower than those in the control group(P<0.05).After treatment,the UPDRS scores of the two groups were lower than those before treatment,and the ADL scores were higher than those before treatment(P<0.05),and the changes in the combined group were more significant(P<0.05).After treatment,the serum levels of 5-HT,BDNF and NE in the two groups were significantly higher than those before treatment(P<0.05),and those in the combined group were significantly higher than those in the control group(P<0.05).The total effective rate of the combined group was 91.11%,which was higher than 71.11%of the control group(P<0.05).there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Wuling Capsule combined with escitalopram in the treatment of Parkinson’s disease can effectively improve the levels of serum 5-HT,BDNF,and NE,reduce the level of serum IL-1β,reduce the inflammatory reaction of patients,and improve the ability of daily living.It is safe and effective.